Updates from National Advisory Committee on Blood and Blood Products

ORBCON update
January 23, 2021

Alan Tinmouth, NAC Vice-chair
Overview

• Subcommittee updates
• Blood Shortages Working Group
• Ig shortages
• CBS PRPR Review Process
• CBS Plasma Protein Products (PPP) and Fresh Blood Components highlights
National Advisory Committee on Blood and Blood Products (NAC)

- NAC collaborates with and provides advice on the utilization management of blood and blood products and transfusion medicine practice to the provincial and territorial (PT) Ministries of Health and Canadian Blood Services (CBS).

Chair: Dr. Oksana Prokopchuk-Gauk
Vice-Chair: Dr. Alan Tinmouth
NAC Work Plan

• The NAC Work Plan is developed following direction of the PTBLC and CBS to NAC

• Documents arising out of the Work Plan have a 3-year schedule for review
  • Schedule reviewed and we confirmed which documents are due for update, including:
    • PCC Recommendations
    • RBC Transfusion Policy Framework
    • National Plan for Shortages of Labile Components
Active NAC Sub Committees

• Guideline Endorsement
• Fibrinogen Concentrate
• Solvent Detergent Plasma
• Prothrombin Complex Concentrates
• National Plan for the Management of Labile Blood Components
• Patient Blood Management
• Immunoglobulin Shortages Plan
• Website Maintenance
Guideline Endorsement Subcommittee
https://www.nacblood.ca/resources/indexendorse.html

Endorsed

• ICTMG Guidance on platelet transfusion for patients with hypoproliferative anemia
• ICTMG Guidance on RBC Specifications for patients with hemoglobinopathies

Under review

• Fetal and neonatal alloimmune thrombocytopenia: recommendations for evidence-based practice, an international approach
Indications for fibrinogen replacement in acquired hypofibrinogenemia:

- Bleeding obstetrical patient and fibrinogen level <2.0g/L
- Massive bleeding or preoperative patient with fibrinogen < 1.5g/L

Suggested adult doses for fibrinogen replacement in acquired hypofibrinogenemia:

- Fibrinogen Concentrate (FC): 2-4g*
- Cryoprecipitate: 10 units (1 unit/10 kg)
- Frozen Plasma: 3-4 units (10-15 mL/kg)

- Pediatric: In published studies, FC dosing has ranged between 30-60 mg/kg.

Products:

- No evidence of superiority of different products (Different FC products; FC vs. Cryoprecipitate).
- FC has a preferred safety profile (decreased transmissible disease risk)
- FC offers logistical advantages, including: a more precise fibrinogen dose, simple preparation without need for thawing, and efficiency of administration.

*off label indication but supported by literature
## NAC Statement on Fibrinogen Replacement


### SUMMARY OF REVISIONS

<table>
<thead>
<tr>
<th>Revision Date</th>
<th>Detail</th>
</tr>
</thead>
<tbody>
<tr>
<td>Next revision - 2021</td>
<td>Expected Spring 2021</td>
</tr>
<tr>
<td>February 2020</td>
<td>Added discussion on RiaSTAP and FIBRYGA as two brands of fibrinogen concentrate now available from CBS</td>
</tr>
<tr>
<td></td>
<td>Added reference for the FIBRES study</td>
</tr>
<tr>
<td></td>
<td>Added statement on fibrinogen concentrate having a favorable safety profile over cryoprecipitate or frozen plasma for fibrinogen replacement</td>
</tr>
<tr>
<td>July 2018</td>
<td>Addition of dosing recommendations for pediatric patients</td>
</tr>
<tr>
<td></td>
<td>Clarified suggested fibrinogen replacement threshold for obstetrical patients</td>
</tr>
</tbody>
</table>
Recommendations for Use of Prothrombin Complex Concentrates in Canada

• Recommendation from 2014
• Literature reviewed since last version and determined that no update needed
• Subcommittee meeting to revise document
  • External experts to be identified and invited
• Will consider addressing use of PCCs outside of warfarin reversal:
  • PCC for reversal of direct oral anticoagulants (DOACs)
  • PCC for other coagulopathies
NAC Blood Shortage Working Group

Interim update posted in March 2020 at start of pandemic.


• Further revisions in progress based on feedback from March 2020 update
Solvent Detergent Plasma – Revised Framework

Revised criteria based on original CADTH report (May 2011). Updated to reflect current clinical practice, but continue to follow original principles outlined by the CADTH Panel of Experts.

S/D Plasma should be considered for:

1. Patients who require a high volume or chronic plasma transfusions (primary qualifier):
   a. Congenital TTP or,
   b. Need for plasmapheresis with plasma as a replacement fluid for conditions such as acquired TTP and HUS or,
   c. Clotting factor deficiencies for which specific licensed concentrates not be readily available

   And who have one of the following secondary qualifiers: ❌
   • Have experienced a recurrent clinically significant allergic reaction to plasma
   • Have an existing lung disorder that would make them more susceptible to effects of TRALI reaction.

2. Any patient who requires plasma but a blood group compatible product is not available in a timely manner.

3. Patients who have had a previous life-threatening reaction to plasma that could be avoided by the use of S/D plasma, where no alternative therapies are available.

Requests outside the above listed would be subject to review by local TM experts and CBS.
Solvent Detergent Plasma – Revised Framework

Revised criteria based on original CADTH report (May 2011). Updated to reflect current clinical practice, but continue to follow original principles outlined by the CADTH Panel of Experts.

S/D Plasma should be considered for:

1. Patients who require a high volume or chronic plasma transfusions (primary qualify):
   a. Congenital TTP or
   b. Need for plasma a replacement fluid for conditions such acquired TTP and HUS
   c. Clotting factor deficiencies for which specific licensed concentrates not readily available

And who have:
   • Have experienced a recurrent clinically significant allergic reaction to plasma
   • Have an existing lung disorder that would make them more susceptible to effects of TRALI

2. Any patient who requires plasma but a blood group compatible product is not available in a timely manner.

3. Patients who have had a previous life-threatening reaction to plasma that could be avoided by the use of S/D plasma, where no alternative therapies are available.

Requests outside the above listed would be subject to review by local TM experts and CBS.
Patient Blood Management

- Request to CBS-PTBLC to include PBM within the scope of the NAC work plan (Aug 2020)
- Patient Blood Management Subcommittee formed
  - Dr. Ryan Lett from Saskatchewan as chair
  - Will draw upon expertise and existing groups in Canada
  - Review of recent European guidelines
Immunoglobulin Shortage Plan

Development of National Plan for Management of Shortage of Immunoglobulin Products is needed

• 2018 Expert Panel recommended development of priority list of patients / conditions
• Shortage of SCIg in Summer 2019
• COVID-19 has led to high likelihood of IVIg shortage in short to medium term
• Accelerated the development of a National Ig Shortages Plan
  • Interim shortage plan approved in July 2020
  • Development of full plan over following 18 months
Interim Immunoglobulin Shortage Plan

• Interim guidance released July 2020 (4-month development)
• Model of green / green advisory / amber / red phase from labile blood components
• Green phase - follow provincial / regional guidelines
• Based on Quebec framework for Ig shortage
• Input from stakeholders across Canada

Considerations for Full National Ig Shortage Plan

- Roles and responsibilities of all stakeholders
- Data sharing including inventory levels
- Adjudication Committees
- Ethical framework
- Allocation criteria
- Medico-legal implications

- Assessment of the effectiveness of inventory phase activities
- Guidance for product switching
- Guidance for use of Ig in research
- Availability and accessibility of alternative therapies
- Tools to document decisions or use
Immunoglobulin Update - October 2020
S. Grenier, Canadian Blood Services

• Potential shortfall of IVIg identified for 2021-22 and 2022-23
  • NEBMC communication in Dec 2020 outlining possible shortage
• Expected disruptions in supply of some brands and vial sizes in 2021

• Pending contract finalization, identified gap for 21/22 and 22/23 were filled by alternative Ig
• Major changes
  • GGL ↓ 50%
  • Gammunex ↑ 33%
  • Privigen ↔ however vial sizes will be impacted (10g and 40g)
  • Panzyga ↑ 100%
  • Octagam* to fill the rest of the gap
• All options for additional sources IVIg exhausted
• Readiness to switch IVIG brands will be required
• CBS will work with hospitals especially large users for potential brand switches
• Provinces responsible for developing local strategies for IVIg management using the Interim National Ig Shortages Plan as a framework
  • NAC is preparing a statement supporting the use of Ig utilization appropriateness guidance documents endorsed within jurisdictions
Overview – Interim review process

CBS health care professionals and scientists provide feedback on clinical and pharmacoeconomic reports.

**Products under review:**
- Hemlibra – CADTH Final Recommendations (Dec)
- Vonvendi- Expert committee recomendation
- Haegarda

**Overview – Interim review process**

- Clinicians
  - Med/Sci Review
  - P’economic review
  - Patient consultation
  - CPEC

- Patient groups
- Clinician groups
- Patient groups
- Blood banks

- CBS as formulary manager
- CDM for listing decision

- Blood banks

**Canadian Blood Services**

**Canadian Blood Services**

**Canadian Blood Services**
CBS PPP utilization

• Immunoglobulin increased by 6.0%
• FVIII utilization decreased by 6.5%
• FEIBA decrease by 52.1%
• Fibrinogen concentrate increase by 30% (71% increase in 2019/20)
• Decrease in cryoprecipitate demand by -57.7% (-39.1% in 2019/20)
Analysis of Immune Globulin

Immune Globulin 5 year trend by grams

- Total thousands of grams | Year on Year % Growth

* FY2020/21 Forecast is based on Sep 30 year-to-date actuals

<table>
<thead>
<tr>
<th>Year</th>
<th>Subcutaneous</th>
<th>Intravenous</th>
<th>Growth %</th>
</tr>
</thead>
<tbody>
<tr>
<td>FY2016/17</td>
<td>660</td>
<td>4,511</td>
<td>8.2%</td>
</tr>
<tr>
<td>FY2017/18</td>
<td>802</td>
<td>4,778</td>
<td>7.9%</td>
</tr>
<tr>
<td>FY2018/19</td>
<td>1,058</td>
<td>4,957</td>
<td>7.8%</td>
</tr>
<tr>
<td>FY2019/20</td>
<td>1,298</td>
<td>5,207</td>
<td>8.2%</td>
</tr>
<tr>
<td>FY2020/21</td>
<td>1,753</td>
<td>5,140</td>
<td>6.0%</td>
</tr>
</tbody>
</table>
### Analysis of Fibrinogen

**Fibrinogen 5 year trend by grams**

<table>
<thead>
<tr>
<th>Total grams</th>
<th>Year on Year % Growth</th>
</tr>
</thead>
<tbody>
<tr>
<td>FY2016/17</td>
<td>77.1%</td>
</tr>
<tr>
<td>FY2017/18</td>
<td>68.2%</td>
</tr>
<tr>
<td>FY2018/19</td>
<td>31.5%</td>
</tr>
<tr>
<td>FY2019/20</td>
<td>71.0%</td>
</tr>
<tr>
<td>FY2020/21</td>
<td>39.0%</td>
</tr>
</tbody>
</table>

* FY2020/21 Forecast is based on Sep 30 year-to-date actuals
Fibrinogen provincial comparison by population - FY2020/21 vs. FY2019/20
Total grams per 1,000 population

* FY2020/21 Forecast is based on Sep 30 year-to-date actuals
Cryoprecipitate Units Issued per 1,000 population by Province
CBS Fresh Blood Component

• Overall decrease in RBC issues
  • O negative percentage increased by from 12.2% to 12.6%
  • Ontario 11.7%
• Platelet units issued stable (-0.7%)
• Frozen plasma issued continues to decrease (-8.4%)
  • AB percentage increased from 16.7% to 19.3%
  • Ontario 20.3%
RBC Units Issued per 1,000 population by Province
% O-Neg RBC Issues of Total RBC Issues by Province
Platelet Units Issued & Fiscal Period Growth Rates
Platelet Units Issued per 1,000 population by Province

- Canada (Excl Quebec)
- Nfld & Labrador
- PEI
- Nova Scotia
- New Brunswick
- Ontario
- Manitoba
- Saskatchewan
- Alberta
- British Columbia
- YU/NWT/NU

Years:
- 2017/18
- 2018/19
- 2019/20
- 2020/21

Values:
- Canada (Excl Quebec): 3.9
- Nfld & Labrador: 0.3
- PEI: 3.0
- Nova Scotia: 6.6
- New Brunswick: 3.3
- Ontario: 4.0
- Manitoba: 3.4
- Saskatchewan: 4.0
- Alberta: 3.3
- British Columbia: 4.0
- YU/NWT/NU: 0.3
Plasma Units Issued & Fiscal Period Growth Rates

![Chart showing Plasma Units Issued and % Change over years from 2010/11 to 2020/21]
% AB Plasma Issues of Total Plasma Issues by Province
National Blood Portfolio Lead: Background

- Since the establishment of the Canadian Blood Services (CBS) in 1998, the following provinces have functioned as the National Blood Portfolio lead:

<table>
<thead>
<tr>
<th>Jurisdiction</th>
<th>Timeframe</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saskatchewan (Transition from Canadian Red Cross Society)</td>
<td>To 1998</td>
</tr>
<tr>
<td>Ontario</td>
<td>1998-2001</td>
</tr>
<tr>
<td>British Columbia</td>
<td>2001-2005</td>
</tr>
<tr>
<td>Nova Scotia</td>
<td>2005-2008</td>
</tr>
<tr>
<td>Alberta</td>
<td>2008-2010</td>
</tr>
<tr>
<td>Newfoundland and Labrador</td>
<td>2010-2013</td>
</tr>
<tr>
<td>Manitoba</td>
<td>2013-2015</td>
</tr>
<tr>
<td>New Brunswick</td>
<td>2015-2017</td>
</tr>
<tr>
<td>Saskatchewan</td>
<td>2017-2019</td>
</tr>
<tr>
<td>Prince Edward Island</td>
<td>2019-2021</td>
</tr>
</tbody>
</table>

Going forward:

<table>
<thead>
<tr>
<th>Jurisdiction</th>
<th>Timeframe</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Ontario</strong></td>
<td><strong>2021-2023</strong></td>
</tr>
<tr>
<td>British Columbia</td>
<td>2023-2025</td>
</tr>
<tr>
<td>Nova Scotia</td>
<td>2025-2029</td>
</tr>
</tbody>
</table>